Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin (NASDAQ:BMRN) and Quidel Corp (NASDAQ:QDEL).
BioMarin (BMRN)
Barclays analyst Gena Wang maintained a Hold rating on BioMarin on August 3 and set a price target of $98. The company’s shares closed on Friday at $99.47.
According to TipRanks.com, Wang is a 5-star analyst with an average return of 25.1% and a 53.4% success rate. Wang covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Sarepta Therapeutics, and Mirati Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioMarin with a $116.85 average price target.
See today’s analyst top recommended stocks >>
Quidel Corp (QDEL)
Barclays analyst Jack Meehan maintained a Buy rating on Quidel Corp on August 3 and set a price target of $78. The company’s shares closed on Friday at $70.87, close to its 52-week high of $72.13.
According to TipRanks.com, Meehan is a 4-star analyst with an average return of 10.6% and a 66.7% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Genomic Health, Thermo Fisher, and Icon plc.
Quidel Corp has an analyst consensus of Strong Buy, with a price target consensus of $73.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
